What's in Universidade Federal do Rio de Janeiro's pipeline?

Universidade Federal do Rio de Janeiro has 13 drugs in our index: 6 marketed, 0 filed, 1 in Phase 3, 5 in Phase 2, 1 in Phase 1.

Which companies overlap with Universidade Federal do Rio de Janeiro's portfolio?

Top competitors by shared drug class: Pfizer, ASST Fatebenefratelli Sacco, Dr. Laurence Klotz, Christopher J. McLeod, Deseret Biologicals, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/universidade-federal-do-rio-de-janeiro.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Universidade Federal do Rio de Janeiro — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Universidade Federal do Rio de Janeiro pipeline: 6 marketed, 0 filed, 1 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

6 marketed 0 filed 1 Phase 3 5 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Phytolacca decandra	Phytolacca decandra	marketed	Botanical/Herbal preparation		Immunology
Lopinavir/r	Lopinavir/r	marketed	Protease inhibitor	HIV protease	Infectious Disease
cyclosporine and sodium carboximethycellulose	cyclosporine and sodium carboximethycellulose	marketed
Melissa officinalis	Melissa officinalis	marketed	Standardized Chemical Allergen [EPC]
sodium carboximethycellulose	sodium carboximethycellulose	marketed	Cellulose derivative; lubricant and protective agent		Ophthalmology; Gastroenterology; Dermatology
Melissa	Melissa	marketed			Other
Phyt.decandra + Melissa offic.	Phyt.decandra + Melissa offic.	phase 3	Herbal combination / Botanical extract		Immunology / Inflammation

Therapeutic area mix

Immunology · 1
Immunology / Inflammation · 1
Infectious Disease · 1
Ophthalmology; Gastroenterology; Dermatology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Pfizer · 2 shared drug classes
ASST Fatebenefratelli Sacco · 1 shared drug class
Dr. Laurence Klotz · 1 shared drug class
Christopher J. McLeod · 1 shared drug class
Deseret Biologicals, Inc. · 1 shared drug class
Donat R. Spahn · 1 shared drug class
Bamrasnaradura Infectious Diseases Institute · 1 shared drug class
ANRS, Emerging Infectious Diseases · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Universidade Federal do Rio de Janeiro:

Cite this brief

Drug Landscape (2026). Universidade Federal do Rio de Janeiro — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universidade-federal-do-rio-de-janeiro. Accessed 2026-05-17.